PLAU and ovarian cancer: Other functional assays using the model and an antibody against the urokinase plasminogen activator (uPA) receptor (u-PAR) revealed that targeting the uPA/u-PAR proteolytic system reduced metastasis and induced apoptosis of ovarian cancer cells [21].